Skip to main content

-

Technology Guidance - Drug

Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy Published on 2 May 2019


Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Rifaximin 550 mg tablet as add-on therapy to lactulose for reducing recurrent episodes of overt hepatic encephalopathy.

Subsidy status

Rifaximin 550 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.


Get Acrobat Readeropens in a new window
Back to Top